Navigation Links
ExonHit and bioMerieux Amend Their Strategic Partnership
Date:1/9/2008

PARIS, January 9 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has signed an amendment to its strategic partnership with bioMerieux in the field of cancer diagnostics. Under the terms of the amendment, ExonHit will gain commercial rights on the diagnostic kits developed through the partnership and bioMerieux will have a greater flexibility to initiate new research and development projects in that field.

The partnership, initiated in October 2005, is based on ExonHit's gene expression analysis expertise and intellectual property, and on bioMerieux's know-how in the field of in vitro diagnostics. Its goal is to develop DNA microarrays to detect cancer markers in blood samples. DNA microarrays are perfectly suitable to detect many nucleic acids allowing the identification of multigenic diseases such as cancers.

Three programs to develop blood-based cancer diagnostics are currently underway: the first is on breast cancer for which a prospective study is ongoing, the second is aimed at colorectal cancers, and the third, targeting prostate cancer, was initiated in January 2007.

As of now, the commercial rights granted will allow ExonHit to market the diagnostic kits developed through the partnership to pharmaceutical companies, or to hospitals taking part in clinical studies, in order to help them recruit patients for their clinical studies.

"This amendment is a major step forward in ExonHit's development because it allows us to consider generating our own source of revenues from products based on our technology which are issued from the collaboration" declared Bruno Tocque, Chairman of the Management Board of ExonHit. "To this end, we are modifying our laboratories and our processes in order to best meet the pharmaceutical industry's specific requirements."

About ExonHit Therapeutics

http://www.exonhit.com
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
6. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
7. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
8. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
9. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
10. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
11. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... July 15 /PRNewswire/ - Scientists in Atlantic Canada have found ... Researchers were investigating the genetic cause of a rare disorder ... on the hands, feet and face to be loose and ... effects on the brain. In the process, researchers found some ...
... , VIENNA, July 15 ... Ib/IIa trial in Alzheimer,s disease patients with its nicotinic alpha-7 ... and EVP-6124 showed good tolerability and safety. , ... Alzheimer,s Association 2009 International Conference on Alzheimer,s Disease (ICAD) in ...
... , , MADISON, Wis., July ... today announced that it has exclusively in-licensed a US-issued patent portfolio on ... (cardiomyocytes) in drug testing. , , ... and Indiana University-Purdue University Indianapolis (IUPUI), covers two ...
Cached Biology Technology:Canadian researchers discover gene related to the appearance of aging 2EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease 2Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 2Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing 3
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... In an insightful Commentary in the November issue ... , Linda Van Horn, PhD, RD, Editor-in-Chief of the ... Professor and Associate Dean, Northwestern University, Feinberg School of ... the 2010 US Dietary Guidelines Advisory Committee (DGAC) Report. ...
... associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to ... takes place, including some forms of cancer. In the current ... at The Wistar Institute describe how viral microRNA small ... allows EBV to hide within cells and evade the ...
... WI, October 25, 2010 A case study published in ... Education by professors at Washington State University studies the ... The journal is published by the American Society of Agronomy. ... young homeless individuals or those involved in the juvenile justice ...
Cached Biology News:DGAC report offers food and nutrition practitioners insights on helping combat obesity epidemic 2DGAC report offers food and nutrition practitioners insights on helping combat obesity epidemic 3MicroRNAs dictate the Epstein-Barr virus' elaborate waiting game, cancer formation 2MicroRNAs dictate the Epstein-Barr virus' elaborate waiting game, cancer formation 3Growing crops in the city 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rad51, N-terminal...
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: